-
Je něco špatně v tomto záznamu ?
The WID-EC test for the detection and risk prediction of endometrial cancer
JE. Barrett, A. Jones, I. Evans, C. Herzog, D. Reisel, A. Olaitan, T. Mould, N. MacDonald, K. Doufekas, C. Newton, EJ. Crosbie, L. Bjørge, N. Colombo, L. Dostalek, L. Costas, P. Peremiquel-Trillas, J. Ponce, X. Matias-Guiu, M. Zikan, D. Cibula,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NIHR300650
Department of Health - United Kingdom
IS-BRC-1215-20007
Department of Health - United Kingdom
PubMed
36533702
DOI
10.1002/ijc.34406
Knihovny.cz E-zdroje
- MeSH
- časná detekce nádoru MeSH
- lidé MeSH
- nádory děložního čípku * diagnóza MeSH
- nádory endometria * diagnóza genetika MeSH
- senzitivita a specificita MeSH
- studie případů a kontrol MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The incidence of endometrial cancer is rising. Measures to identify women at risk and to detect endometrial cancer earlier are required to reduce the morbidity triggered by the aggressive treatment required for advanced endometrial cancer. We developed the WID-EC (Women's cancer risk IDentification-Endometrial Cancer) test, which is based on DNA methylation at 500 CpG sites, in a discovery set of cervical liquid-based cytology samples from 1086 women with and without an endometrial cancer (217 cancer cases and 869 healthy controls) with a worse prognosis (grade 3 or ≥stage IB). We validated the WID-EC test in an independent external validation set of 64 endometrial cancer cases and 225 controls. We further validated the test in 150 healthy women (prospective set) who provided a cervical sample as part of the routine Swedish cervical screening programme, 54 of whom developed endometrial cancer within 3 years of sample collection. The WID-EC test identified women with endometrial cancer with a receiver operator characteristic area under the curve (AUC) of 0.92 (95% CI: 0.88-0.97) in the external set and of 0.82 (95% CI: 0.74-0.89) in the prospective validation set. Using an optimal cutoff, cancer cases were detected with a sensitivity of 86% and a specificity of 90% in the external validation set, and a sensitivity and specificity of 52% and 98% respectively in the prospective validation set. The WID-EC test can identify women with or at risk of endometrial cancer.
Centre for Cancer Biomarkers CCBIO Department of Clinical Science University of Bergen Bergen Norway
Department of Laboratory Medicine Division of Pathology Karolinska Institutet Stockholm Sweden
Department of Obstetrics and Gynecology Haukeland University Hospital Bergen Norway
European Translational Oncology Prevention and Screening Institute Hall in Tirol Austria
Hospital Na Bulovce Prague Czech Republic
Istituto Europeo di Oncologia Milan Italy
Research Institute for Biomedical Aging Research Universität Innsbruck Innsbruck Austria
University Hospitals Bristol NHS Foundation Trust Bristol UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003613
- 003
- CZ-PrNML
- 005
- 20230425140745.0
- 007
- ta
- 008
- 230418s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ijc.34406 $2 doi
- 035 __
- $a (PubMed)36533702
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Barrett, James E $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK $u Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria
- 245 14
- $a The WID-EC test for the detection and risk prediction of endometrial cancer / $c JE. Barrett, A. Jones, I. Evans, C. Herzog, D. Reisel, A. Olaitan, T. Mould, N. MacDonald, K. Doufekas, C. Newton, EJ. Crosbie, L. Bjørge, N. Colombo, L. Dostalek, L. Costas, P. Peremiquel-Trillas, J. Ponce, X. Matias-Guiu, M. Zikan, D. Cibula, J. Wang, K. Sundström, J. Dillner, M. Widschwendter
- 520 9_
- $a The incidence of endometrial cancer is rising. Measures to identify women at risk and to detect endometrial cancer earlier are required to reduce the morbidity triggered by the aggressive treatment required for advanced endometrial cancer. We developed the WID-EC (Women's cancer risk IDentification-Endometrial Cancer) test, which is based on DNA methylation at 500 CpG sites, in a discovery set of cervical liquid-based cytology samples from 1086 women with and without an endometrial cancer (217 cancer cases and 869 healthy controls) with a worse prognosis (grade 3 or ≥stage IB). We validated the WID-EC test in an independent external validation set of 64 endometrial cancer cases and 225 controls. We further validated the test in 150 healthy women (prospective set) who provided a cervical sample as part of the routine Swedish cervical screening programme, 54 of whom developed endometrial cancer within 3 years of sample collection. The WID-EC test identified women with endometrial cancer with a receiver operator characteristic area under the curve (AUC) of 0.92 (95% CI: 0.88-0.97) in the external set and of 0.82 (95% CI: 0.74-0.89) in the prospective validation set. Using an optimal cutoff, cancer cases were detected with a sensitivity of 86% and a specificity of 90% in the external validation set, and a sensitivity and specificity of 52% and 98% respectively in the prospective validation set. The WID-EC test can identify women with or at risk of endometrial cancer.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a časná detekce nádoru $7 D055088
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 12
- $a nádory děložního čípku $x diagnóza $7 D002583
- 650 12
- $a nádory endometria $x diagnóza $x genetika $7 D016889
- 650 _2
- $a senzitivita a specificita $7 D012680
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jones, Allison $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
- 700 1_
- $a Evans, Iona $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
- 700 1_
- $a Herzog, Chiara $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria $1 https://orcid.org/000000021572498X
- 700 1_
- $a Reisel, Daniel $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
- 700 1_
- $a Olaitan, Adeola $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
- 700 1_
- $a Mould, Tim $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
- 700 1_
- $a MacDonald, Nicola $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
- 700 1_
- $a Doufekas, Konstantinos $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK
- 700 1_
- $a Newton, Claire $u University Hospitals Bristol NHS Foundation Trust, Bristol, UK $u University of Bristol, Bristol, UK
- 700 1_
- $a Crosbie, Emma J $u Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK $u Division of Gynaecology, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK $1 https://orcid.org/0000000302848630
- 700 1_
- $a Bjørge, Line $u Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway $u Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway $1 https://orcid.org/0000000202402770
- 700 1_
- $a Colombo, Nicoletta $u Istituto Europeo di Oncologia, Milan, Italy $u University of Milano-Bicocca, Milan, Italy
- 700 1_
- $a Dostalek, Lukas $u Hospital Na Bulovce, Prague, Czech Republic $u Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Costas, Laura $u Unit of Molecular Epidemiology and Genetics in Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain $1 https://orcid.org/000000032755302X
- 700 1_
- $a Peremiquel-Trillas, Paula $u Unit of Molecular Epidemiology and Genetics in Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain $1 https://orcid.org/0000000286361725
- 700 1_
- $a Ponce, Jordi $u Department of Gynecology and Obstetrics, Hospital Universitari de Bellvitge, IDIBELL. Hospitalet de Llobregat, Barcelona, Spain
- 700 1_
- $a Matias-Guiu, Xavier $u Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, CIBERONC. Hospitalet de Llobregat, Barcelona, Spain
- 700 1_
- $a Zikan, Michal $u Hospital Na Bulovce, Prague, Czech Republic $u Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Cibula, David $u Department of Obstetrics and Gynecology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Wang, Jiangrong $u Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/000000020001503X
- 700 1_
- $a Sundström, Karin $u Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000268650224
- 700 1_
- $a Dillner, Joakim $u Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000185886506
- 700 1_
- $a Widschwendter, Martin $u European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria $u Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK $u Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria $1 https://orcid.org/0000000277788380
- 773 0_
- $w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 152, č. 9 (2023), s. 1977-1988
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36533702 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425140742 $b ABA008
- 999 __
- $a ok $b bmc $g 1924347 $s 1189822
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 152 $c 9 $d 1977-1988 $e 20230117 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
- GRA __
- $a NIHR300650 $p Department of Health $2 United Kingdom
- GRA __
- $a IS-BRC-1215-20007 $p Department of Health $2 United Kingdom
- LZP __
- $a Pubmed-20230418
